

# Ac-YVAD-cmk

Cat. No.: HY-16990

CAS No.: 178603-78-6

Molecular Formula:  $C_{24}H_{33}CIN_4O_8$ Molecular Weight: 540.99

Target: Caspase Pathway: **Apoptosis** 

Storage: -20°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

**Product** Data Sheet

# **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (184.85 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8485 mL	9.2423 mL	18.4846 mL
	5 mM	0.3697 mL	1.8485 mL	3.6969 mL
	10 mM	0.1848 mL	0.9242 mL	1.8485 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.84 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.84 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective caspase-1 (IL-1beta converting enzyme, ICE)) inhibitor with neuroprotective and anti-inflammatory effects. Ac-YVAD-cmk effectively suppresses the expression of IL-1 $\beta$ and IL-18. Ac-YVAD-cmk inhibits pyroptosis in many diseases <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	Caspase-1
In Vitro	Ac-YVAD-cmk (40 $\mu$ M or 80 $\mu$ M) reduces the expression of IL-1 $\beta$ and IL-18 in activated microglia in vitro <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Ac-YVAD-cmk treatment (1 $\mu$ g/rats; SD rat; injected into the left lateral ventricle) significantly decreases the protein levels of caspase-1 (p20), mature IL-1 $\beta$ /IL-18 compared with the ICH group <sup>[2]</sup> .

Ac-YVAD-cmk (rats with ac-YVAD-cmk at a dose of 12.5  $\mu$ mol/kg) significantly reduces mortality from 83 to 33% using Log Rank analysis<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

# **CUSTOMER VALIDATION**

- Int Immunopharmacol. 2024 Jan 16:128:111537.
- J Leukoc Biol. 2023 Jul 25; qiad088.
- Molecules. 2023, 28(3), 1312.
- Food Chem Toxicol. 2023 Jun 9;113886.
- Research Square Preprint. 2023 Oct 23.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Wang F, et al. Alcohol accumulation promotes esophagitis via pyroptosis activation. Int J Biol Sci. 2018;14(10):1245-1255. Published 2018 Jul 13.

[2]. Liang H, et al. Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats. Int Immunopharmacol. 2019;75:105771.

[3]. Mathiak G, et al. Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses. Br J Pharmacol. 2000;131(3):383-386.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA